M&A / Deals Jeito Capital secures over $1.2bn for new biopharma investments Pharmaceutical Business ReviewThe milestone increases Jeito's assets under management to 1.6bn, following the 534m closure of Jeito I in 2021.M&A / DealsRead full story pharminent April 9, 2026 (Last updated: April 9, 2026) Pharmaceutical Business Review The milestone increases Jeito’s assets under management to 1.6bn, following the 534m closure of Jeito I in 2021. M&A / DealsRead full story Post navigation Previous: FDA seeks permanent future for rare pediatric priority review vouchersNext: EverSea Medicines to acquire Hasten Biopharmaceuticals Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
